GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It does several things at once: it prompts the pancreas to release insulin when blood sugar rises, it slows how quickly the stomach empties, and it acts on the brain to reduce appetite. GLP-1 receptor agonists are medications that mimic this hormone, and they have become widely known under brand names such as Ozempic, Wegovy, Mounjaro and others.
Originally developed to treat type 2 diabetes, this class of medication was found to produce significant weight loss, which is why it has moved into obesity treatment and, from there, into wide public attention. These are prescription medicines, given by injection (with some newer oral forms), and they are not the same thing as the supplements and peptides sometimes marketed alongside them.
The reason GLP-1 belongs in a longevity library is not a promise of longer life. It is that metabolic health, blood sugar control and healthy body composition are genuinely connected to long-term health, and this class of drug affects all three. The science here is real, prescribed, and studied, which also means it carries the responsibilities of real medicine.
The evidence base for GLP-1 receptor agonists is substantial by supplement standards and sits in the realm of prescription medicine. Large trials have established their effect on blood sugar in type 2 diabetes and on weight in obesity, and more recent trials have shown cardiovascular benefits in specific patient groups. This is a well-studied class of drug with clear, measured effects.
What is less certain is the longer-term picture in people who do not have diabetes or obesity but take these drugs for general optimisation or modest weight loss. That use is far less studied, and the balance of benefit and risk in that population is not the same as in the trial populations where benefit was demonstrated. Evidence for a specific patient is strongest when that patient resembles the people actually studied.
There are also open questions about what happens after stopping, including the well-documented tendency for weight to return, and about long-term effects over many years, which are still being gathered.
Common side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, especially when starting or increasing the dose. For most people these ease over time, but for some they are significant.
More serious, though less common, considerations include pancreatitis, gallbladder problems, and a need for caution in people with certain thyroid cancer history (a specific contraindication for some drugs in the class). Rapid weight loss can also mean loss of muscle alongside fat, which matters a great deal for long-term health and is a reason these drugs are meant to be paired with adequate protein and resistance exercise.
A serious modern risk sits outside the medicine itself: a grey market of unregulated GLP-1 products, compounded or counterfeit, sold without prescription or oversight. These carry real danger, from incorrect dosing to unknown contents. A GLP-1 medication should come through a legitimate prescription and pharmacy, never an unverified online seller.
This is prescription medicine, so a doctor is not optional, it is the route. Speak to a qualified professional if you are considering a GLP-1 medication, and be fully honest about your medical history, including any thyroid conditions, pancreatitis, gallbladder issues, eating disorders, pregnancy or plans to conceive, and all other medications. Seek prompt medical advice if you develop severe abdominal pain, persistent vomiting, or signs of an allergic reaction while taking one. Never obtain these medicines outside a regulated prescription.
Cost varies by medication, dose, and whether it is prescribed for diabetes or obesity, and whether privately or through a health service. Private prescription costs are ongoing and monthly, and stopping typically means the benefits reverse. Prices are indicative only. This entry is not an endorsement and not a recommendation to take any specific medication.
Large randomised trials of GLP-1 receptor agonists in type 2 diabetes and obesity. Cardiovascular outcome trials in relevant patient groups. NICE and NHS guidance on GLP-1 medications and their approved uses. MHRA and regulatory warnings on unlicensed and counterfeit GLP-1 products. Educational information only. Speak to a qualified healthcare professional. GLP-1 medications are prescription-only and must be obtained through a regulated prescription.